StockData
Lite Strategy, Inc. logo

Lite Strategy, Inc. (LITS) company profile

LITSNasdaqFinance ServicesFiscal year ends June 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.79−0.06 (-7.20%)

Close on Nov 17, 2026Market cap $24.17MP/E –Yield –

About Lite Strategy

Finance Services, SIC 6199

Lite Strategy, Inc. is a biopharmaceutical company engaged in pre-clinical development programs for non-oncologic disease indications, after historically developing cancer therapies. The company's drug candidate pipeline features voruciclib, an orally administered cyclin-dependent kinase 9 inhibitor, and zandelisib, an oral selective PI3Kδ inhibitor. In addition to pharmaceutical research, the company maintains Litecoin as a primary treasury reserve asset and manages covered call option strategies on its digital asset holdings. Potential customers and commercial partners include biotechnology and pharmaceutical companies, research institutions, and healthcare collaborators targeted for out-licensing, program sales, or clinical development partnerships.

Because the company is focused on early-stage drug candidate research and treasury management, it does not operate commercial retail stores, manufacturing facilities, or consumer service locations. Operational, regulatory, and patent activities are carried out primarily in the United States, alongside patent holdings across international jurisdictions. The provided text does not disclose the location of the company's corporate headquarters.

Summary of the business section of Lite Strategy's latest annual report, written by StockData.

Company profile

Company

Legal name
Lite Strategy, Inc.
Headquarters
San Diego, CA
Address
9920 Pacific Heights Blvd, Suite 150 92121
Phone
(858) 369-7100
Employees
5, Jun 30, 2026
Industry
Finance Services
Incorporated in
Delaware
Fiscal year ends
June 30
Auditor
Deloitte and Touche LLP, San Diego, California

Stock & identifiers

Ticker
LITS
Former tickers
MEIP until Sep 15, 2025
Exchange
Nasdaq
IPO date
Dec 18, 2003
Shares outstanding
30M, Sep 22, 2026
Public float
$43.00M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Apr 17, 2023; 1-for-6 reverse, Dec 19, 2012; 1-for-10 reverse, Mar 31, 2010
SEC CIK
1262104
CUSIP
55279B202
ISIN
US55279B2025
FIGI
BBG000BSGT68
Share class FIGI
BBG001SBWG10
LEI
529900A43X33ON524197
EIN
51-0407811

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Justin J. FileCEO, CFO and Secretary, Director–
Nicholas GloverDirector2,000
Frederick W. DriscollDirector1,875
James P. FlynnDirector125,000
Joshua RiezmanDirector–
Charles Benjamin LeeDirector292,397
Steven D. WoodDirector72,092
Thomas C. ReynoldsDirector500

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$1.58M$1.43M–$18–
FY2025$912.67K$893.20K–$48–
FY2024
David MUrso
$894.91K$220.79K$730.91K$57–
FY2024
David Urso
$894.91K$233.57K$730.91K$57–
FY2023
Daniel Gold
$2.45M$1.85M$772.49K$54$109
FY2023
Daniel PGold
$2.45M$1.86M$772.49K$54$109

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryIncentive payOtherTotalvs. prior year
Justin J. File
Acting Chief Executive Officer, Chief Financial Officer
$541.67K$371.00K–$912.67K+48%
David M. Urso
Former President and Chief Executive Officer
$53.53K–$880.52K$934.05K+4%
Richard G. Ghalie
Former Chief Medical Officer
$43.87K–$664.27K$708.13K-16%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of June 30, 2026, we had five employees whom all reside in the United States and were engaged in business development, finance, information systems or administrative support.”

Corporate history

Events identified from SEC filings

DateEventDetails
Dec 5, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 10, 2025Name changeName changed from MEI Pharma, Inc. to Lite Strategy, Inc.
Oct 25, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 26, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 3, 2023ListingRegistration of securities on an exchange (Form 8-A)
Apr 28, 2023MergerRegistration of securities for a merger or exchange offer (S-4)
May 17, 2022Late filingNotification of late filing
May 13, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 28, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 23, 2012Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 6, 2012Name changeName changed from MARSHALL EDWARDS INC to MEI Pharma, Inc.
Mar 30, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 13, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 11, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 1, 2011MergerRegistration of securities for a merger or exchange offer (S-4)
Jan 27, 2011Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 19, 2011Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 19, 2010Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 20, 2010Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 24, 2010Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 20, 2010Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 19, 2010Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 22, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 14, 2008Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 13, 2006DelistingNotice of delisting from exchange (Form 25)
Oct 21, 2004Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 16, 2004Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 18, 2003IPOInitial public offering priced (424B4 prospectus)

See a number that looks wrong?